Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Verona Pharma PLC VRNA

Healthcare

Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual... see more

Add To Watchlist

Recent & Breaking News (NDAQ:VRNA)

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

GlobeNewswire February 2, 2021

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

GlobeNewswire February 2, 2021

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

GlobeNewswire January 14, 2021

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

GlobeNewswire January 5, 2021

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

GlobeNewswire November 9, 2020

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

GlobeNewswire October 29, 2020

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update

GlobeNewswire October 22, 2020

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

GlobeNewswire October 13, 2020

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

GlobeNewswire September 8, 2020

Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference

GlobeNewswire September 2, 2020

Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020

GlobeNewswire August 24, 2020

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020

GlobeNewswire August 14, 2020

Verona Pharma Announces August 2020 Virtual Investor Conference Participation

GlobeNewswire August 3, 2020

Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update

GlobeNewswire July 30, 2020

Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription

GlobeNewswire July 17, 2020

Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program

GlobeNewswire May 14, 2020

Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference

GlobeNewswire May 1, 2020

Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020

GlobeNewswire April 30, 2020

Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update

GlobeNewswire April 23, 2020

Verona Pharma plc: Results of AGM

GlobeNewswire April 16, 2020